English

Kenko Breast AI+

🔴 < Kenko Breast AI+

Turning multiparametric
breast MRI into quantitative,
explainable clinical insight.

freepik__assistant__52274

What is Kenko Breast AI+

AI-powered decision support for breast MRI

Breast cancer is the most common cancer in women worldwide. Breast MRI is the most sensitive tool for detecting and characterising disease, yet its complexity creates a growing bottleneck in clinical practice. Each exam generates thousands of images that radiologists must analyse under time pressure, often relying on qualitative interpretation. As imaging volumes rise and specialist capacity remains limited, hospitals face increasing pressure to deliver faster, more consistent decisions while maintaining the highest standards of care.
Kenko Breast AI+ supports radiologists by transforming multiparametric breast MRI into quantitative, explainable imaging biomarkers that are clear, visual, and clinically interpretable. By reducing reading time, lowering false positives and false negatives, and providing objective insight into tumour behaviour, it strengthens diagnostic confidence in daily practice and tumour boards. The result is faster, more defensible decisions for clinicians and measurable value for hospitals — improving workflow efficiency, reducing unnecessary procedures, and elevating the quality of breast cancer care.

Designed for the
radiologist’s workflow

How Kenko Breast AI+ Works

Kenko Breast AI+ integrates seamlessly into routine breast MRI interpretation, supporting radiologists without changing how exams are acquired or read. After MRI acquisition, the radiologist securely uploads the multiparametric MRI study to Kenko Breast AI+, where the system processes the full exam and generates quantitative, explainable imaging biomarker maps.

Radiologists review these biomarker maps alongside the original MRI images, enabling clearer lesion characterisation, more consistent interpretation, and stronger evidence for multidisciplinary tumour board discussions. By transforming complex MRI data into visually interpretable, physiology-linked insight, Kenko Breast AI+ helps radiologists move from image overload to quantitative clarity while maintaining full clinical control over interpretation and reporting.

KENKO breast AI+ workflow

Download from
PACS anonymized
CASE FILE
MRI DICOM images
(Zip file)
Create Case
Upload to
KENKO Breast AI+
User
Radiologist
Viewer
The user consults
Kenko Imalytics' biomarkers
and the raw MRI images
for the diagnosis
Kenko Interpretation Support
The user establishes
conclusions from the maps
and creates the final diagnosis

A New Standard in Breast
MRI Interpretation​

From detection to understanding tumour behaviour

Clinical performance

See all

Clinical performance

Closing the gap between detection and diagnostic confidence
MRI is the most powerful tool for understanding tumour behavior, yet it remains underused because interpretation is complex and time-consuming. What used to take 40 minutes, now takes around 10 minutes.

Fewer false positives. Fewer missed cancers

Quantitative imaging biomarkers improve lesion characterisation and diagnostic consistency.

Quantitative evidence, not probability scores

Physiology-linked biomarkers reveal vascularisation, cellularity, and tumour
heterogeneity.

*In the optimal-case scenario, when DCE is acquired with +20 UltraFast dynamics and a temporal resolution of 4 seconds, specificity rose to 98.54% ± 2.2%.
This significantly decreases the number of FPs, allowing much better specificity to be obtained, as the device is useful in differentiating benign from
malignant lesions in a much more consistent way. Additional clinical investigations are underway to further confirm this clinical evidence

Radiologists

See all

Radiologists

Transform thousands of MRI images into clear biomarker maps that accelerate
reading and reporting

Objective evidence for complex cases
Quantitative biomarkers reduce inter-reader variability and support confident interpretation.

Stronger tumour board discussions
Visual, explainable biomarker maps provide evidence radiologists can present and defend.

Hospitals and Health Systems

See all

Hospitals and Health Systems

Clinical excellence with operational efficiency

  • Reduced unnecessary biopsies and follow-up procedures
  • Faster reporting and optimised imaging workflows
  • Improved diagnostic consistency across radiologists
  • Strategic differentiation in advanced breast imaging

Multidisciplinary Oncology Teams

See all

Multidisciplinary Oncology Teams


Built for , tumour boards

Kenko Breast AI+ generates shared quantitative biomarker maps that allow radiologists, oncologists, surgeons, and pathologists to discuss tumour behaviour using the same objective visual evidence.

This supports:

  • Earlier treatment decisions
  • Clearer clinical alignment
  • Reduced uncertainty in complex case

While most AI tools focus on finding lesions, Kenko Breast AI+ helps clinicians understand tumour behaviour, enabling faster, clearer, and more confident decisions across the oncology pathway.

The biomarker logic behind Kenko Breast AI+
Kenko Breast AI+ interprets tumour behaviour using complementary MRI biomarkers derived from perfusion, diffusion, and anatomical context.
Kenko Breast AI+ goes beyond detecting suspicious regions in breast MRI. The system extracts quantitative imaging biomarkers from multiparametric MRI to reveal how tumours behave biologically. By analysing vascular dynamics, tissue cellularity, and anatomical context together, Kenko Breast AI+ helps radiologists interpret tumour behaviour with greater clarity and confidence.
Three Biomarker Dimensions

Perfusion biomarkers

Perfusion biomarkers
Understanding vascular behaviour

Contrast-enhanced MRI captures how contrast agents circulate through tissue. Kenko analyses both standard and ultrafast contrast dynamics to identify patterns associated with tumour vascularisation and aggressiveness. Early contrast uptake behaviour provides valuable insight into tumour activity and helps distinguish suspicious lesions.

Diffusion biomarkers

Diffusion biomarkers
Understanding tissue cellularity

Breast tissue has an anisotropic structure that is not fully captured by conventional diffusion imaging. Kenko uses diffusion tensor imaging (DTI) and advanced modelling to extract stable biomarkers that reflect tissue cellularity and structural organisation. By reducing noise and improving robustness, Kenko makes diffusion information clinically usable for breast MRI interpretation

Multiparametric interpretation

Multiparametric interpretation
Integrating biological signals

Kenko Breast AI+ integrates perfusion and diffusion biomarkers together with anatomical MRI information such as T2 sequences when relevant. This multiparametric approach enables a more complete characterisation of tumour behaviour, supporting clearer lesion interpretation and more informed clinical decisions

By combining complementary imaging biomarkers, Kenko Breast AI+ helps radiologists move from detecting lesions to understanding tumour behaviour.

Product Capabilities

What Kenko Breast AI+ can do

Kenko Breast AI+ provides a set of clinically focused functionalities designed to support
radiologists in breast MRI interpretation, reporting, and multidisciplinary decision-making
through the interpretable use of quantitative imaging biomarkers derived from
multiparametric MRI.

Analytical Functionalities

Quantitative Imaging Biomarker Maps

Converts multiparametric breast MRI into pixel-wise quantitative imaging biomarker maps reflecting key tissue properties such as cellularity and vascular behaviour, enabling objective and reproducible assessment beyond qualitative visual MRI reading.

Perfusion Dynamics Analysis (Standard DCE and, when available, Ultrafast DCE)

Analyses contrast-enhancement dynamics from standard DCE perfusion and, when available, ultrafast DCE acquisitions. Depending on the MRI acquisition protocol, Kenko Breast AI+ can assess these perfusion datasets separately or in combination, characterising vascular behaviour across different temporal phases of contrast uptake.

Tumour Aggressiveness Assessment

Uses quantitative perfusion dynamics to identify enhancement patterns associated with biologically more active disease, differentiating the most aggressive regions within a lesion, and supporting clinical prioritisation and treatment planning.

Tumour Subtype Characterisation

Identifies characteristic quantitative enhancement profiles associated with different tumour phenotypes, providing additional analytical insight into lesion biology.

Optimised Diffusion Analysis (DTI Noise Reduction and Biomarker Extraction)

Processes diffusion tensor imaging data to reduce noise and extract clinically meaningful quantitative biomarkers related to tissue cellularity.

Multiplanar Biomarker Visualisation

Displays quantitative biomarker maps in axial, sagittal and coronal planes, spatially synchronised to support accurate localisation and confident interpretation.

Synchronous Navigation Across Biomarker Maps

Allows radiologists to navigate synchronously across biomarker maps derived from multiple MRI sequences, ensuring consistent spatial correspondence during image review.

Maximum Intensity Projection (Selective MIP)

Generates maximum intensity projection views of biomarker maps. 

Quantitative Lesion and Tissue Characterisation

Supports quantitative characterisation of breast lesions and surrounding tissue based on imaging biomarker maps derived from multiparametric MRI.

Structured Reporting and Results Export

Allows radiologists to record a final case conclusion and export biomarker maps and visual outputs for reporting, documentation and multidisciplinary discussion.

Together, these capabilities transform complex multiparametric breast MRI into quantitative, interpretable evidence that supports clearer interpretation, consistent reporting and confident multidisciplinary decision-making.

Clarity that saves lives

Explore how Kenko Imalytics supports your clinical practice

Discover how quantitative, explainable imaging biomarkers can bring clarity to MRI

interpretation and support more confident decisions across the oncology pathway.

Get in touch

Turning complexity
into clinical confidence

KENKO IMALYTICS
Universitat Politècnica de València
Carrer Pedro Duque, Edificio 9B
Camí de Vera, s/n
46022 Valencia
Spain
HOME
CONTACT
Linkedin-in

Check your email for your login credentials to
access Kenko Breast AI+.

Your login details have been sent to the email address linked to your authorised account. Please
follow the instructions included in that email to
access the platform securely.

Thank you.